SHARE

Belgium-Netherlands, France, Germany, InnoStars, Ireland-UK, Scandinavia, Spain, Accelerator, 2017

Twenty promising start-ups win €7k to develop business plans

4th August 2017

Winners will go on to compete for up to €30 000 in a pitch competitions

 

In the first elimination round of a competition that will yield prizes of up to €30 000, EIT Health InnoStars awarded 20 candidates grants of €7 000 to fund development of their business plans.
InnoStars received 78 eligible project proposals, from start-ups in Italy, Poland, Portugal, Greece and Hungary. After the first evaluation cut-off, undertaken by international experts, the TOP 20 shortlist has now been published, with winners from all five countries.

The 20 winners include a device that ensures high improvement in the early diagnosis of cardiovascular and chronic obstructive pulmonary diseases, and also interactive platforms/applications, like a therapy system that enables a unique, at-home, motor skills learning process for children who have suffered a stroke.

Assisted by experienced consultants, the 20 selected companies have until the end of September to submit their business plans. Based on a review of these plans, the top eight companies will be invited to compete with a final pitch in front of an international jury consisting of healthcare professionals, representatives of EIT Health core industrial partners and market experts. The three companies deemed to be the best in the pitch contest will be awarded up to €30 000.

For further enquiries please contact:

Anita Fuzi, anita.fuzi@eithealth.eu

EIT Health Bootcamp selects 11 female-led start-ups

EIT Health Bootcamp selects 11 female-led start-ups

Connecting women-led teams to mentors and investors

Find out more

EIT Health selecting three Supervisory Board members

EIT Health selecting three Supervisory Board members

Independent members sought; apply by 23 May

Find out more

Bridgehead announces first start-ups for 2021

Bridgehead announces first start-ups for 2021

Helping SMEs expand in Europe and beyond

Find out more